Quinazoline ditosylate salt compounds

Details for Australian Patent Application No. 2001273071 (hide)

Owner Glaxo Group Limited

Inventors Sacchetti, Mark Joseph; Roschangar, Frank; Osterhout, Martin Howard; Mcclure, Michael Scott

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2001273071

PCT Pub. Number WO02/02552

Priority 60271845 27.02.01 US; 60215508 30.06.00 US

Filing date 28 June 2001

Wipo publication date 14 January 2002

Acceptance publication date 8 September 2005

International Classifications

C07D 405/04 Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 221/00 Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups

C07D 239/00 Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61P 035/00 Antineoplastic agents

A61P 017/06 Drugs for dermatological disorders

A61K 031/519 - ortho- or peri-condensed with heterocyclic rings

A61K 031/517 - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 417/04 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

8 September 2005 Application Accepted

  Published as AU-B-2001273071

12 January 2006 Standard Patent Sealed

6 September 2007 Extension granted

  Glaxo Group Limited Quinazoline ditosylate salt compounds Address for Service: Level 22 367 Collins Street, Melbourne VIC 3000 Date extended term due to expire on 28/06/2021

20 March 2008 Extension granted

  Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 28 Jun 2007 For the goods Lapatinib Asditosylate Monohydrate Tykerb Extension of Term of patent pursuant to Section 77 expires on 28 Jun 2022

20 January 2011 Assignment Registered

  Glaxo Group Limited The patent has been assigned to GlaxoSmithKline LLC Assignments Registered

24 February 2011 Offer to Surrender

  Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford , Middlesex UB6 0NN, the Patentee of Letters Patent 2001273071 dated 22.12.2005 for an invention titled ' Quinazoline ditosylate salt compounds' offers to surrender the said Letters Patent. Any person desiring to be heard before the said offer to surrender is accepted must lodge a request to be heard within one month from the date of this journal.

21 April 2011 Offer to Surrender

  The offer by the Patentee Glaxo Group Limited to surrender Letters Patent 2001273071 which was advertised in the Official Journal of 24.02.2011 has been accepted and the Letters Patent has been revoked in accordance with Section 137 of the Patents Act.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001273072

2001273070